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Abstract: Atopic dermatitis (AD) is among the most common inflammatory skin diseases in 
children and adults in industrialized countries. Up to one-third of adults (probably a smaller 
proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment 
is usually based on systemic therapies. The currently available therapeutics are limited, and 
AD management becomes challenging in most cases. Over the last few years, new advances in 
the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the 
identification of specific therapeutic targets and new molecules have been tested. Dupilumab 
is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able 
to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements 
in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promis-
ing biological target treatment option for Th2 cell-mediated atopic immune response that 
characterizes AD.
Keywords: dupilumab, atopic dermatitis, eczema, IL-4, IL-13, biologics
Introduction
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases 
affecting up to 25% of children in industrialized countries.1 One-third of cases persist 
into adulthood, comprising a prevalence of 2%–10%.2–4 AD is not just a skin disease 
as it may represent the first manifestation of the so-called atopic march, a spectrum 
of interconnected disorders, including rhinitis, conjunctivitis, and asthma, that may 
follow skin symptoms later in life.2–6
Because the prevalence of AD is lower in rural and nonindustrialized countries,4 
the hygiene hypothesis, in which the lack of exposure to antigens in early life would 
induce immune imbalance, favoring a proinflammatory Th2 response that drives the 
immune dysregulation in AD, has been proposed.4,7,8
Immunopathogenesis of AD
AD pathogenesis represents a complex mechanism, including a defective epider-
mal barrier, caused by an altered expression of keratinocyte differentiation genes 
(eg, cornified cell envelope-related genes) and an abnormal content of extracellular 
lipids, resulting in increased transepidermal water loss and permeation to allergens, 
irritants, and microbes.9–11
Beside this intrinsic impairment of the keratinocyte differentiation process, 
AD lesional skin shows a marked infiltration of T cells, both CD4+ and CD8+ 
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T cells, dendritic cells (DCs), Langerhans cells, and other 
immune cells, including eosinophils, mast cells, and IgE-
producing plasma cells.9 Classically, AD is considered as 
a Th2-dominant disease, as an enhanced signal of the Th2 
pathway is detected in AD lesional skin and, to a lesser 
strength, in non-lesional skin.5,12,13 The increased expression 
of Th2-derived cytokines, namely, IL-4, IL-5, IL-13, and 
IL-31, is correlated with high levels of Th2 chemoattractants 
and activating factors such as CCL-17, CCL-18, CCL-22, 
CCL-26, CCL-27, and TSLP.14,15
iL-4 and iL-13
The centrality of the Th2 cytokines is due to their capability of 
1) inducing IgE class switching; 2) promoting Th2 survival; 
3) recruitment of eosinophils; 4) mediating pruritus; and 
5) inhibiting keratinocyte terminal differentiation and AMP 
production (Figure 1). Particularly, IL-4 and IL-13 are consid-
ered as the Th2-signature cytokines and master mediators in 
AD pathogenesis as they act on various cells involved in AD 
(ie, keratinocytes, T cells, DCs, and eosinophils), signaling 
through the same receptor, the IL-4Rα receptor. Although 
the immune response is polarized toward a Th2 response, 
other T-cell subsets participate in AD pathogenesis, includ-
ing T22 cells and both CD4+ and CD8+ T cells producing 
IL-22-, IL-17-, and IFNγ-secreting cells.16–19 Based on the 
dominant pathways driving AD inflammation, intrinsic AD 
may be distinguished from the extrinsic form. Indeed, the 
extrinsic form (~80% of AD cases) shows high IgE serum 
levels associated with a Th2-skewed immune polarization 
and a less pronounced T22 signal, whereas the intrinsic form 
(the remaining 20%) is characterized by low IgE titers and a 
Th2 response, with a marked upregulation of the Th17 and 
Th22 axes.20 In this scenario, key mediators, such as IL-4, 
IL-13, and IL-22, have been identified as therapeutic targets 
for the development of new agents that selectively inhibit 
their signaling. One of the promising agents that is currently 
being developed for the treatment of AD is dupilumab, an 
IL-4Rα antagonist.
Clinical phenotypes and 
endophenotypes of AD toward 
personalized treatment
AD is characterized by a wide range of heterogeneity either 
in the onset (ie, infant–adolescent–adult), course, and 
presentation (different manifestation of eczema among either 
the age, the clinical features, or the area involved) or in the 
comorbidities (eg, the presence of atopy and normal IgE dis-
tinguishes an intrinsic AD from an extrinsic or IgE-associated 
AD).21,22 All these variants are due to the complex interactions 
between individual genetic and environmental factors involved 
in AD that lead to epidermal barrier dysfunction, innate and 
adaptive abnormalities of the immune system (an initial Th2 
phase followed by a chronic Th1 phase), and cutaneous micro-
biome dysbiosis. Despite all these AD variants, the diagnosis 
is clinical and no diagnostic biomarkers dissecting AD from 
other inflammatory disorders have been identified yet.23–27 
Since AD involves more than one subtype, the discovery, 
validation, and use of objective markers will achieve a more 
personalized clinical and treatment approach.28
Nowadays, treatment choice is based on disease severity 
and symptoms, namely, pruritus and the “trouble sleeping”. 
The commonly used assessment tools, both in trial setting 
and in daily practice, include the Eczema Area and Severity 
Index (EASI), a composite score assessing objective signs, 
and the SCORing Atopic Dermatitis (SCORAD), evaluating 
both signs and symptoms. Management and treatment in 
the short (flares) and long periods may become challenging 
because of the individual symptomatic variability and the 
limited array of therapeutics currently available.29–31
Current treatment for AD
AD treatment includes “basic therapy” focused on emollients 
and moisturizing compounds, on the avoidance of specific or 
unspecific triggering factors, and on educational programs/
psychological counseling.30–32
First-line pharmacological treatment is based on the use 
of topical medications: topical corticosteroids and topical 
calcineurin inhibitors, namely, tacrolimus and pimecrolimus. 
Topical agents represent the mainstay of therapy in patients 
with mild-to-moderate disease and are used either for the 
management of exacerbation or, more recently, for proactive 
therapy.29–31,33 The long-term intermittent (twice weekly) 
Figure 1 Th2-derived cytokines whose activity is neutralized by dupilumab 
antagonizing their receptor.
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anti-inflammatory therapy aims to prevent relapses and to 
keep the skin free of eczema. This strategy has been proven 
successful in improving the clinical management and is, 
notably, associated with pharmacoeconomic benefits.29–31
Phototherapy (ultraviolet A1 [UVA1] wavelength or 
ultraviolet B [UVB] 311 nm) can be adjuncted in controlling 
challenging cases not responsive to topical treatments, such 
as second-line treatment, with good results.29–31
Up to one-third of adults (probably a smaller proportion 
in childhood) suffer from moderate-to-severe AD, whose 
recommended treatment is usually based on systemic thera-
pies. The treatment choice depends on AD severity, patient’s 
features, physician’s experience, and drug availability.5 
Although the majority of evidence exists in adult populations, 
four systemic immunosuppressive drugs have also demon-
strated to be efficacious in adults and children: cyclosporine, 
mycophenolate mofetil, methotrexate, and azathioprine.33,34 
Among them, cyclosporine is the only drug approved for 
the treatment of AD. According to the European Guidelines, 
other systemic medications are suggested in case of no 
response to cyclosporine and/or when contraindications to 
cyclosporine occur.29–31,33 No biologic drugs targeting AD-
signature mediators have been approved yet. Nevertheless, 
off-label use, sometimes successful, of biologics approved 
for other indications, such as omalizumab, ustekinumab, and 
rituximab, has been reported.35
Thus, the current therapeutic paradigm in AD is limited 
and its management becomes challenging in most cases. 
Furthermore, some side effects of these medications, such as 
nephrotoxicity and risk of hypertension during cyclosporine 
treatment, limit their use.
Dupilumab: developing the new era 
in the treatment of AD
Over the last few years, new advances in the understanding 
of AD pathogenic mechanisms and inflammatory pathways 
have led to the identification of specific therapeutic targets, 
similar to what occurred in the past decade in psoriasis.28,36 
Th2 cells and their key cytokines, such as IL-4, IL-13, 
IL-5, TSLP, and IgE, constitute emerging targets for new 
compounds that have been or are currently being tested 
in clinical trials.28,37 In the last few years, some biologics, 
such as omalizumab (anti-IgE) and mepolizumab (anti-
IL-5), have been previously tested in patients with AD, 
although no significant benefits were described.33,38–40 On 
the contrary, the blockade of IL-4/IL-13-mediated signaling 
through the receptor antagonism was proven to be a success-
ful therapeutic strategy in AD. Dupilumab is a fully human 
monoclonal antibody directed against the IL-4 receptor α 
subunit, which is a component of Type I and Type II IL-4 
receptors and the IL-13 receptor system. Because of this 
binding, dupilumab is able to effectively inhibit the IL-4 
and IL-13 signaling, with pivotal effect in Th2 inflamma-
tory atopic response (Figure 1).41 IL-4 and IL-13 increase 
the expression of important chemokines such as TARC and 
eotaxin-3 and attract Th2 cells and eosinophils. They are 
also important in AD because they contribute directly to 
barrier dysfunction (acting on keratinocyte differentiation 
and barrier protein, lipids, and production of antimicrobial 
peptides).42
Mechanistic study
To define dupilumab’s spectrum of action on AD skin, a 
comprehensive gene expression analysis was performed, 
comparing pretreatment with posttreatment lesional skin 
and non-lesional skin. Biopsy specimens were obtained 
from 18 adult patients with moderate-to-severe chronic AD 
participating in two Phase I multicenter, randomized, double-
blind, placebo-controlled trials testing weekly subcutane-
ous injections of dupilumab 150 or 300 mg or placebo for 
4 weeks.42 Disease severity, assessed by EASI, was signifi-
cantly improved in adults treated with dupilumab compared 
to the placebo group as EASI-50, representing at least 50% 
reduction in the EASI score relative to baseline, was achieved 
by all but one patient in the substudy treated with 300 mg of 
dupilumab versus none in the placebo group.42
Clinical improvement was associated with significant 
dose-dependent changes from baseline in the defined AD 
transcriptome (meant as the array of differentially expressed 
genes between lesional and non-lesional AD skin) detected 
in lesional skin by using microarrays in the dupilumab group 
compared with the placebo arm of the study.13 The altered 
expression detected in pretreatment lesional skin improved 
after dupilumab treatment, with 821 genes whose expression 
was modulated by 300 mg dupilumab versus 275 placebo-
modulated probes.42 In particular, dupilumab downregulated 
a large set of genes codifying for inflammatory mediators and 
epidermal proliferation markers, while it upregulated genes 
involved in the structural, lipid metabolism, and barrier-related 
functions. Particularly, dupilumab was able to suppress key 
pathogenic circuits mediated by Th2-derived products, as 
demonstrated by the reduction in IL-4 and IL-13 levels at 
skin lesions observed in dupilumab-responder patients.42 
As confirmed by quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR), dupilumab was able 
to suppress the expression of proinflammatory genes related 
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not only to a Th2 and eosinophil response (eg, CCL13 and 
CCL26) but also to the IL-17/IL-22 signaling and Th1 
pathway.42 Overall, these mechanistic changes induced by 
dupilumab, including the suppression of immune cell activa-
tion (ie, T cells, DCs, and eosinophils) and the amelioration of 
keratinocyte proliferation and differentiation, were correlated 
with clinical improvement of AD, and these effects were dose 
dependent in dupilumab-treated patients.
Phase I and II studies
The first controlled studies (Phase I and II) testing dupil-
umab for the treatment of AD were performed in 2014.35,43 
In adults with moderate-to-severe AD, dupilumab, admin-
istered as 4- to 12-week monotherapy or in association 
with topical corticosteroids, achieved rapid and significant 
improvements.
Reduction in disease severity was observed, starting 
from the first week, obtaining 74% decrease in EASI after 
12 weeks of treatment. Similarly, a significant reduction in 
pruritus levels (55.7% in the treatment group versus 15% 
in the placebo group) was noted, with positive repercussion 
on patients’ quality of life (Table 1). Clinical improvements 
were proportional to the drug dose.43,44 During the dupilumab 
treatment, early and sustained improvement of patient-
reported outcomes (PROs) in sleep, mental health, and 
health-related quality of life were highlighted.43,45
Safety data showed no evidence of drug-related serious 
adverse events or organ toxicity, with nasopharyngitis and 
headache among the most common side effects.44
The clinical improvement was correlated with Th2-related 
biomarker changes at serum and tissue levels and normaliza-
tion of gene expression in lesional skin, appearing similar 
to the non-lesional gene expression profile.43 The latter data 
suggest that the epidermal abnormalities associated with AD 
might be somehow reduced with dupilumab treatment.43,46
Overall, the vigorous effects of dupilumab in improving 
clinical and laboratory signs confirm the pivotal pathogenic 
role of IL-4 and IL-13 signaling in adulthood AD and further 
support the use of Th2 cytokine antagonists in the treatment 
of this disease.43,47
Phase III trials
In 2016, two randomized, placebo-controlled, worldwide 
Phase III trials were conducted, enrolling 671 adult patients 
suffering from moderate-to-severe AD whose disease was 
inadequately controlled by topical treatment (patients suf-
fering from AD variants were included, eg, intrinsic, extrin-
sic, with early onset, or with late onset). In these studies, 
dupilumab significantly improved the signs and symptoms T
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cell-mediated atopic immune response that characterizes 
AD and asthma.33,43,48 Interestingly, mepolizumab (anti-
IL-5) and omalizumab (anti-IgE), which have been studied 
in asthma with the same success as that of dupilumab, did 
not achieve enough results in AD. This fact may underlie 
a pivotal role of IL-4 and IL-13 among the Th-2 signal 
cytokines in AD.
Dupilumab initiates a decade that will be probably char-
acterized by a great number of clinical trials in these areas, 
focusing not only on IL-4 and IL-13 but also on IL-31, IL-22, 
and TSLP, providing new hopes and insights for future thera-
peutic (and maybe prevention) approaches in AD.33,35,50
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